BDR Pharma seeks CL for 95% cheaper version of cancer drughttps://indianexpress.com/article/news-archive/web/bdr-pharma-seeks-cl-for-95-cheaper-version-of-cancer-drug/

BDR Pharma seeks CL for 95% cheaper version of cancer drug

The company said it has filed the CL application Under Section 84 of Patents Act,1970 (as amended up to 2005) and Rule 96 of the Patents (Amendment) Rules,2006.

Drug firm BDR Pharmaceuticals has applied for a compulsory licence (CL) to market generic version of US-based Bristol-Myers Squibb’s (BMS) cancer drug Dasatinib,sold under ‘Sprycel’ brand,promising to offer the product at price cheaper by over 95 per cent for a month’s treatment.

The Mumbai-based firm has applied to the Controller of Patents,Mumbai,seeking the CL for “ease of availability” and “affordability” of the drug through its generic version. “As against BMS’s monthly treatment cost of Rs 1,65,680 per patient,BDR will offer the product at Rs 8,100 per month,which works out to around 95.2 per cent cheaper,” BDR Pharma said in a statement.

The company said it has filed the CL application Under Section 84 of Patents Act,1970 (as amended up to 2005) and Rule 96 of the Patents (Amendment) Rules,2006.